Skip to main content

REGN

Stock

REGN

Stock
Health Care
Biotechnology

Performance overview

REGN Price
Price Chart

Forward-looking statistics

Beta
0.30
Risk
25.98%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Company info

SectorHealth Care
IndustryBiotechnology
Employees13K
Market cap$110.5B

Fundamentals

Enterprise value$49.8B
Revenue$14.1B
Revenue per employee—
Profit margin31.94%
Debt to equity9.20

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$39.36
Dividend per share$3.52
Revenue per share$130.88
Avg trading volume (30 day)$792M
Avg trading volume (10 day)$625M
Put-call ratio—

Macro factor sensitivity

Growth+0.9
Credit+1.6
Liquidity+0.7
Inflation-2.1
Commodities-0.2
Interest Rates-0.6

Valuation

Dividend yield0.66%
PEG Ratio12.08
Price to sales4.20
P/E Ratio12.08
Enterprise Value to Revenue3.54
Price to book1.97

Upcoming events

Next earnings dayApril 29, 2025
Next dividend day—
Ex. dividend dayMay 20, 2025

News

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

Zacks Investment Research (July 3, 2025)
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

CNBC Television (June 23, 2025)
Regeneron Pharma Shares Rise Over 3% After Key Signal

REGN climbs over 16 points after the alert

Benzinga (June 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free